EnsoData, an innovator in AI healthtech solutions, announced a $20 million Series B financing led by Questa Capital. This new capital will enable EnsoData to accelerate adoption of its AI-powered sleep medicine solutions, improving the sleep care pathway for, in the US alone, an estimated 54 million patients suffering from […]
Product/Vendor Updates
Nihon Kohden Advances Remote Neurology Care with Second-Generation Live View Panel Pro
Nihon Kohden, a global leader in medical device innovation for high-precision patient monitoring and diagnostics, proudly announces the launch of its second-generation Live View Panel Pro™, a specialized virtual health system designed to transform remote neurophysiological assessment and treatment. The upgraded platform combines real-time interactive viewing, integrated two-way intercom and […]
ProSomnus Introduces EVO Guided for the Treatment of Obstructive Sleep Apnea
ProSomnus Sleep Technologies announces EVO Guided. EVO Guided is a new precision, custom oral device for the treatment of Obstructive Sleep Apnea (“OSA”). FDA cleared, patented and covered by most medical insurances, EVO Guided is the first oral device bioengineered to dilate the oropharynx and the velopharynx for optimal therapeutic […]
Harmony Strengthens Patent With ANDA Settlement
Harmony Biosciences Holdings, Inc., today announced a settlement agreement with Lupin Limited, resolving the patent infringement litigation related to Lupin’s Abbreviated New Drug Application (ANDA) for a generic version of WAKIX® (pitolisant hydrochloride). As part of the agreement, litigation in the United States District Court for the District of Delaware will […]
Avadel’s LUMRYZ Receives FDA Orphan Drug Designation for Idiopathic Hypersomnia
Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM has been granted Orphan Drug Designation (ODD) from the U.S. Food & Drug Administration (FDA) for the treatment of Idiopathic Hypersomnia (IH). Specifically, ODD was granted based on the plausible hypothesis that LUMRYZ may […]
The Accuracy of Home Sleep Testing
Home sleep tests (HSTs) have emerged as a convenient and cost-effective alternative to traditional in-lab polysomnography (PSG) for diagnosing sleep disorders, particularly obstructive sleep apnea (OSA). Over the years, HST technology has advanced significantly, leading to improvements in accuracy and reliability. In this article, I will explore the accuracy of […]
DormoVision X Launches at SLEEP 2025
Revolutionizing sleep health with an all-in-one, AI-driven diagnostics platform. Delivering real-time physiological data monitoring and sleep analysis that matches the accuracy and quality of in-lab studies, with the comfort and convenience of at-home testing. Dormotech, a leader in advancing sleep diagnostics through innovative, clinically validated solutions, is proud to launch […]
Emerging OSA Treatments and the Evidence
Neuroscientists have found the average person processes roughly 74 gigabytes of information every day.1 That is the equivalent of watching 16 movies, reading more than 200,000 words, or scrolling on TikTok for approximately 200 hours. In other words, we are inundated with information from every angle — social media, websites, […]
Are We Truly Open to Change in the Approach to OSA?
Although there are more than half a billion individuals worldwide affected by moderate to severe obstructive sleep apnea (OSA), the vast majority still remain undiagnosed and many are untreated.1-2 Healthcare in the United States is facing shortages at every level—and these shortages are projected to increase sharply over the next […]
The Diagnostic Journey for Narcolepsy
In previous editions, we’ve talked a lot about how diagnosis is only the first part of the journey with narcolepsy. It’s true that there are many pieces to managing the disorder that follow, but that diagnosis is something we really want to hone in on in this edition. The information […]













